Closing the rare disease diagnostic gap can improve patient care and outcomes. Did you know that one in 10 Americans have a ...

When Roche previewed the Axelios technology in February, a Jefferies analyst called the next-generation sequencing platform ...

Cornell researchers have found that a new DNA sequencing technology can be used to study how transposons move within and bind to the genome. Transposons play critical roles in immune response, ...

Esophageal cancer, which is cancer of the swallowing tube, has only a 22.2% five-year relative survival rate, but early ...

AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost efficiency, giving laboratories of all sizes the freedom to customise their workflows and explore a wider array of ...

The launch was supported by collaborations with institutions such as the Hartwig Medical Foundation and Broad Clinical Labs.

Increased adoption of clinical whole-genome sequencing is advancing diagnostics for rare diseases, which affect 15 million American children SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Illumina, Inc.

We spoke to David Klenerman, co-developer of sequencing by synthesis, to find out how his work heralded the next generation ...

Newborn babies admitted to the hospital's neonatal intensive care unit (NICU) rely on the quick decisions and rapid action of the medical team responsible for them. DNA testing is critical to ...

SEATTLE--(BUSINESS WIRE)--Phase Genomics, Inc., a leader in genomic technology development, today announced the launch of its new ProxiMeta Starter and Elite Bundles, comprehensive product offerings ...

In just a few decades, DNA sequencing technologies evolved from slow, manual processes to rapid, automated ones, making ...

Roche debuts Axelios, a gene sequencer targeting academic and research facilities, to compete with Illumina's dominance in ...